Supplementary Figure 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Authors :: Olatoyosi Odenike
Wendy Stock
Richard A. Larson
Walter M. Stadler
L. Austin Doyle
Scott E. Smith
Sachdev P. Thomas
Philip Dy
Ehab L. Atallah
Loren Joseph
Poluru L. Reddy
Kevin Shannon
Greg Koval
Xavier Poire
Margaret Green
Harry P. Erba
Theodore Karrison
Mark H. Kirschbaum
Leslie Popplewell
Rangesh Kunnavakkam
Ernesto Diaz-Flores
Neil M. Iyengar
Emily Curran
Nitin Jain
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: PDF file - 339K, Flow cytometry histograms of serial levels of p-ERK and p-mTOR in patient samples.

Tools